vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and IMAX CORP (IMAX). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $125.2M, roughly 1.6× IMAX CORP). IMAX CORP runs the higher net margin — 0.5% vs -14.6%, a 15.1% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 35.1%). IMAX CORP produced more free cash flow last quarter ($28.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 25.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
AXSM vs IMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $125.2M |
| Net Profit | $-28.6M | $637.0K |
| Gross Margin | — | 57.6% |
| Operating Margin | -13.8% | 19.3% |
| Net Margin | -14.6% | 0.5% |
| Revenue YoY | 65.0% | 35.1% |
| Net Profit YoY | 61.9% | -88.0% |
| EPS (diluted) | $-0.55 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $125.2M | ||
| Q3 25 | $171.0M | $106.7M | ||
| Q2 25 | $150.0M | $91.7M | ||
| Q1 25 | $121.5M | $86.7M | ||
| Q4 24 | $118.8M | $92.7M | ||
| Q3 24 | $104.8M | $91.5M | ||
| Q2 24 | $87.2M | $89.0M | ||
| Q1 24 | $75.0M | $79.1M |
| Q4 25 | $-28.6M | $637.0K | ||
| Q3 25 | $-47.2M | $20.7M | ||
| Q2 25 | $-48.0M | $11.3M | ||
| Q1 25 | $-59.4M | $2.3M | ||
| Q4 24 | $-74.9M | $5.3M | ||
| Q3 24 | $-64.6M | $13.9M | ||
| Q2 24 | $-79.3M | $3.6M | ||
| Q1 24 | $-68.4M | $3.3M |
| Q4 25 | — | 57.6% | ||
| Q3 25 | — | 63.1% | ||
| Q2 25 | — | 58.5% | ||
| Q1 25 | — | 61.4% | ||
| Q4 24 | — | 52.2% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 49.4% | ||
| Q1 24 | — | 59.3% |
| Q4 25 | -13.8% | 19.3% | ||
| Q3 25 | -27.0% | 27.2% | ||
| Q2 25 | -24.5% | 15.6% | ||
| Q1 25 | -46.9% | 19.3% | ||
| Q4 24 | -61.1% | 10.3% | ||
| Q3 24 | -59.8% | 21.2% | ||
| Q2 24 | -89.5% | 3.2% | ||
| Q1 24 | -89.7% | 15.3% |
| Q4 25 | -14.6% | 0.5% | ||
| Q3 25 | -27.6% | 19.4% | ||
| Q2 25 | -32.0% | 12.3% | ||
| Q1 25 | -48.9% | 2.7% | ||
| Q4 24 | -63.1% | 5.7% | ||
| Q3 24 | -61.7% | 15.2% | ||
| Q2 24 | -91.0% | 4.0% | ||
| Q1 24 | -91.1% | 4.1% |
| Q4 25 | $-0.55 | $0.02 | ||
| Q3 25 | $-0.94 | $0.37 | ||
| Q2 25 | $-0.97 | $0.20 | ||
| Q1 25 | $-1.22 | $0.04 | ||
| Q4 24 | $-1.54 | $0.09 | ||
| Q3 24 | $-1.34 | $0.26 | ||
| Q2 24 | $-1.67 | $0.07 | ||
| Q1 24 | $-1.44 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $151.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $337.9M |
| Total Assets | $689.8M | $894.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $151.2M | ||
| Q3 25 | $325.3M | $143.1M | ||
| Q2 25 | $303.0M | $109.3M | ||
| Q1 25 | $300.9M | $97.1M | ||
| Q4 24 | $315.4M | $100.6M | ||
| Q3 24 | $327.3M | $104.5M | ||
| Q2 24 | $315.7M | $91.6M | ||
| Q1 24 | $331.4M | $81.0M |
| Q4 25 | $88.3M | $337.9M | ||
| Q3 25 | $73.7M | $349.5M | ||
| Q2 25 | $73.1M | $320.4M | ||
| Q1 25 | $53.2M | $299.5M | ||
| Q4 24 | $57.0M | $299.5M | ||
| Q3 24 | $92.9M | $289.4M | ||
| Q2 24 | $102.9M | $267.2M | ||
| Q1 24 | $144.0M | $258.8M |
| Q4 25 | $689.8M | $894.0M | ||
| Q3 25 | $669.3M | $889.6M | ||
| Q2 25 | $639.8M | $868.6M | ||
| Q1 25 | $596.7M | $848.3M | ||
| Q4 24 | $568.5M | $830.4M | ||
| Q3 24 | $561.5M | $847.6M | ||
| Q2 24 | $548.2M | $827.4M | ||
| Q1 24 | $545.7M | $824.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $29.4M |
| Free Cash FlowOCF − Capex | $-18.7M | $28.0M |
| FCF MarginFCF / Revenue | -9.6% | 22.3% |
| Capex IntensityCapex / Revenue | 0.0% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $29.4M | ||
| Q3 25 | $1.0M | $67.5M | ||
| Q2 25 | $-32.4M | $23.2M | ||
| Q1 25 | $-43.4M | $7.0M | ||
| Q4 24 | $-26.2M | $11.5M | ||
| Q3 24 | $-18.6M | $35.3M | ||
| Q2 24 | $-30.1M | $35.0M | ||
| Q1 24 | $-53.5M | $-11.0M |
| Q4 25 | $-18.7M | $28.0M | ||
| Q3 25 | $988.0K | $64.8M | ||
| Q2 25 | $-32.4M | $20.9M | ||
| Q1 25 | $-43.7M | $5.3M | ||
| Q4 24 | $-26.2M | $6.9M | ||
| Q3 24 | $-18.7M | $34.2M | ||
| Q2 24 | $-30.2M | $33.5M | ||
| Q1 24 | $-53.6M | $-12.1M |
| Q4 25 | -9.6% | 22.3% | ||
| Q3 25 | 0.6% | 60.7% | ||
| Q2 25 | -21.6% | 22.8% | ||
| Q1 25 | -36.0% | 6.1% | ||
| Q4 24 | -22.1% | 7.4% | ||
| Q3 24 | -17.9% | 37.3% | ||
| Q2 24 | -34.6% | 37.6% | ||
| Q1 24 | -71.4% | -15.3% |
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.3% | 1.9% | ||
| Q4 24 | 0.0% | 5.0% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.1% | 1.8% | ||
| Q1 24 | 0.1% | 1.4% |
| Q4 25 | — | 46.11× | ||
| Q3 25 | — | 3.27× | ||
| Q2 25 | — | 2.06× | ||
| Q1 25 | — | 2.99× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | — | 2.54× | ||
| Q2 24 | — | 9.78× | ||
| Q1 24 | — | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
